XNK Therapeutics adds three scientific advisors to bolster platform technology

Dr. Fredrik Schjesvold is Head of Oslo Myeloma Center, in Oslo, Norway, head of the Norwegian myeloma association, president of the Nordic Myeloma Study Group and a member of the European Myeloma Network board. He is national investigator of 36 clinical trials in multiple myeloma and principal investigator for four academic studies. He is a co-author of ESMO and IMWG guidelines, as well as lead author of the Norwegian myeloma guidelines.  Dr. Fredrik Schjesvold is Head of Oslo Myeloma Center,...

Dr. Fredrik Schjesvold is Head of Oslo Myeloma Center, in Oslo, Norway, head of the Norwegian myeloma association, president of the Nordic Myeloma Study Group and a member of the European Myeloma Network board. He is national investigator of 36 clinical trials in multiple myeloma and principal investigator for four academic studies. He is a co-author of ESMO and IMWG guidelines, as well as lead author of the Norwegian myeloma guidelines. 

Dr. Johan Lund is currently Head of Myeloma Section at Karolinska University Hospital's hematology department. He received his medical degree from University of Gothenburg and his PhD in hematology from Karolinska Institutet.

"XNK Therapeutics is working hard to develop cancer treatments with the company's novel NK cell-based therapies and having the right expertise is critical to supporting our efforts," said Johan Aschan, CMO of XNK Therapeutics. "We are thrilled that Ola, Fredrik and Johan are willing to support the company at such a pivotal moment in its growth.

CONTACT:

For more information, please contact:

Johan Liwing, CEO, XNK Therapeutics
Tel: +46 706 70 36 75
E-mail: [email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/xnk-therapeutics-ab/r/xnk-therapeutics-adds-three-scientific-advisors-to-bolster-platform-technology,c3454283

The following files are available for download: